NCT07162506View on ClinicalTrials.gov

DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 30, 2027

Study Completion Date

August 30, 2030

Conditions
Esophageal Cancer
Interventions
PROCEDURE

Surgery

Radical esophagectomy + mediastinal lymph node dissection

RADIATION

Radiotherapy

Radiotherapy: 50.4 Gy/28f

DRUG

Chemotherapy

Chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles

Trial Locations (1)

Unknown

RECRUITING

Tianjin Cancer Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT07162506 - DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI | Biotech Hunter | Biotech Hunter